Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
WEST LAFAYETTE, Ind., Aug. 1, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced financial results for the second quarter ending June 30, 2013, and provided a business update.
Help employers find you! Check out all the jobs and post your resume.
